SCHEMBL24310424

SCHEMBL24310424

Cc1ccccc1-c1nc(NSc2cnn(C)c2)nc(Oc2ccc(N3CCN(C)CC3)cc2)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.41
▸ PDE10A Q9Y233 1/20 0.41
▸ MAP4K1 Q92918 1/20 0.38
▸ CCNK O75909 3/20 0.37
▸ CCND3 P30281 3/20 0.37
▸ CDK9 P50750 3/20 0.37
▸ CDK6 Q00534 3/20 0.37
▸ CCNA2 P20248 2/20 0.37
▸ CDK2 P24941 2/20 0.37
▸ EGFR P00533 4/20 0.36
▸ CTSC P53634 2/20 0.36
▸ HRH4 Q9H3N8 2/20 0.36
▸ ITK Q08881 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ BLK P51451 1/20 0.35
▸ BMX P51813 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ IGF1R P08069 2/20 0.34
▸ MAP3K7 O43318 2/20 0.34
▸ TTK P33981 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24309916 0.92 EGFR (0.39) MAP4K1EGFRCTSCHRH4ITK
SCHEMBL24310428 0.90 MAP4K1 (0.38) PDE2APDE10AMAP4K1CCNKCCND3
SCHEMBL24310158 0.89 MAP4K1 (0.37) PDE2APDE10AMAP4K1CCNKCCND3
SCHEMBL24309719 0.89 MAP4K1 (0.37) PDE2APDE10AMAP4K1CCNKCCND3
SCHEMBL24309882 0.89 MAP4K1 (0.37) PDE2APDE10AMAP4K1CCNKCCND3
SCHEMBL24309386 0.88 JAK2 (0.37) PDE2APDE10AMAP4K1CCNKCCND3
SCHEMBL24310171 0.88 CTSC (0.36) PDE2APDE10AMAP4K1CCNKCCND3
SCHEMBL24309392 0.87 BRD4 (0.37) PDE2APDE10AMAP4K1CCNKCCND3
SCHEMBL24310733 0.87 IGF1R (0.34) MAP4K1IGF1R
SCHEMBL24310709 0.86 DRD2 (0.33) MAP4K1CDK2EGFRJAK2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback